Home / News / News & Updates / pCODR Releases Initial Recommendation of Opdivo pCODR Releases Initial Recommendation of Opdivo pCODR releases initial recommendation of Opdivo (nivolumab) for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required. This is a great news for NSCLC patients! We hope to see more like this for other types of lung cancer. Read more Initial Recommendation (pdf) News News & Updates Current News February 2024 Newsletter In this Issue: Nova Scotia Screening Program Announced! Lung Ambition Awards Opportunity Listen to our Lung Cancer Voices Podcast Upcoming Events Read More November 2023 Newsletter In this issue: LCAM Activities November 2023 Newsletter Read More Questions To Ask Clinical Trials Share Your Story Community Activities Make A Donation Peer to Peer Network
Home / News / News & Updates / pCODR Releases Initial Recommendation of Opdivo pCODR Releases Initial Recommendation of Opdivo pCODR releases initial recommendation of Opdivo (nivolumab) for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required. This is a great news for NSCLC patients! We hope to see more like this for other types of lung cancer. Read more Initial Recommendation (pdf) News News & Updates Current News February 2024 Newsletter In this Issue: Nova Scotia Screening Program Announced! Lung Ambition Awards Opportunity Listen to our Lung Cancer Voices Podcast Upcoming Events Read More November 2023 Newsletter In this issue: LCAM Activities November 2023 Newsletter Read More Questions To Ask Clinical Trials Share Your Story Community Activities Make A Donation Peer to Peer Network